The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its ...

Merck says Keytruda boosted overall survival in phase 3 ovarian cancer trial and cut death risk in bladder cancer combo data.

The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.

Sales of Merck’s longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts ...

Merck & Co. said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its blockbuster cancer drug Keytruda for certain patients with ...

To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...

Merck & Co.'s Keytruda in combination with an antibody-drug conjugate from Pfizer and Astellas Pharma led to a 47% reduction in the risk of tumor recurrence, progression or death in patients with ...

Merck (NYSE:MRK) reported positive Phase 3 SMART trial results for ENFLONSIA, showing protection against RSV in high risk ...

New KEYTRUDA indications are expected to preserve Merck's top line. Click here to read why MRK stock remains a great buy upon ...

Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the ...